Breaks Categories: News

FridayOct 01, 2021 10:25 am

NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released it unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total revenues reaching an estimated  $1.4 million, an increase of 128.5% compared to the same period in 2020; gross profit margin of 61.4%, an increase of 16.1 percentage points from the same six-month period in 2020; and the average selling price of CDA-based tests being  $71, also an increase over last year’s average price for the same period. The company also reported a decrease in non-GAAP…

Continue Reading

FridayOct 01, 2021 10:13 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Appoints New Executives, Promotes Team Members

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has named two new executive team members. The company has named Dr. Amir Inamdar as the chief medical officer for its European operations and Dr. Geoff Varty as the  new head of research & development. In addition, the company has made some internal promotions, naming Lori Challenger as chief compliance, ethics & administrative officer and Robert Mino as general counsel. A trained psychiatrist and pharmaceutical physician with more than two decades of clinical and drug-development experience, Inamdar has deep expertise in progressing numerous drugs from preclinical development…

Continue Reading

FridayOct 01, 2021 10:11 am

NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Changes Neem Oil into Novel Nanoemulsion through Patented UST Platform

Pressure BioSciences’ (OTCQB: PBIO) patented Ultra Shear Technology(TM) (“UST”) platform has produced stable, high-quality neem oil nanoemulsions. The nanoemulsions are designed to provide safe, natural, and environmentally friendly pesticides, which can be used to mitigate agricultural losses and decrease the spread of disease by insects. These nanoemulsions combine with water and then remain suspended for months, in the process having a protective impact on ingredients that would typically deteriorate. Neem oil is a common preventative treatment for malaria, but dosing has been a challenge in the past. PBIO’s breakthrough development could provide solutions to that challenge. In addition, the nanoemulsions…

Continue Reading

ThursdaySep 30, 2021 1:35 pm

NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has started its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of epidermolysis bullosa (“EB”). According to the company, this is the first time cannabinol has advanced to a Phase 2 clinical trial to be studied as a therapeutic option to treat a disease. The study will be conducted in seven different countries at 11 sites; the countries include Austria, Germany, Greece, France, Italy, Israel and Serbia. The company has filed clinical trial applications in all seven countries and has received approval from…

Continue Reading

ThursdaySep 30, 2021 1:12 pm

NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Enters First-of-Its-Kind Partnership with Paradigm Healthcare

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced a first-of-its-kind partnership with Paradigm Healthcare, an independent clinical laboratory located in St. Simons, Georgia, with a focus on high complexity, clinical toxicology, to bring state-of-the-art testing to Ketamine Infusion Centers LLC (“KIC”). Under the partnership, KIC will have access to Paradigm’s Benchmark UDT(TM) toxicology solution that utilizes LC/MS/MS test methods to identify and accurately measure drug compounds in the body, ensuring the highest quality toxicology results and clinically relevant test data to support medical decision making. “Paradigm’s Benchmark testing platform brings state-of-the-art drug testing…

Continue Reading

ThursdaySep 30, 2021 12:50 pm

NetworkNewsBreaks – ISW Holdings Inc. (ISWH) Exceeds Milestones to Trigger Bonus $1.7M in Bitmain Miners

ISW Holdings (OTC: ISWH) (transitioning to “BlockQuarry,” pending name change), a Nevada-based portfolio company with primary commercial-stage operations in cryptocurrency mining, today announced that it has surpassed agreed-upon milestones related to the performance of its common stock price. The company will, therefore, receive an additional 150 Bitmain S19 95TH/s miners from Minerset, a Delaware LLC, due to negotiated milestone clauses included in the asset purchase agreement reached between the two companies in August. According to the update, the company leveraged its shares of Preferred B stock to purchase its initial tranche of 400 miners. As a part of the contract, ISW…

Continue Reading

ThursdaySep 30, 2021 11:57 am

NetworkNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Commences Trading on the OTCQX Best Market

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced that it has graduated from the OTCQB Venture Market to now trade on the OTCQX Best Market, the highest tier of OTC Markets Group. “Receiving approval to trade on the OTCQX is an important milestone for MINDCURE, validating the outstanding efforts of our entire team to build a leading psychedelics company and to drive value for patients, therapists, clinics and shareholders,” said Kelsey Ramsden, president and chief executive officer of MINDCURE. “Trading on the OTCQX Market enhances the…

Continue Reading

ThursdaySep 30, 2021 11:36 am

NetworkNewsBreaks – DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF) Releases Q2 2022 Financial Results, Corporate Update

DigiMax Global (CSE: DIGI) (OTC: DBKSF), a company that provides artificial intelligence (“AI”) and cryptocurrency technology solutions, is reporting its financial results for both the three-month and six-month period ended on July 31, 2021. Worth noting is the announcement that the company saw unrealized gain on digital currencies for the period of C$2.65 million while net equity in the company reached C$17.39 million in Q1 2022 and a further C$1.9 million in Q2 2022. Since unrealized digital currency gains are not included in the net income/loss report under IFRS but are recognized under comprehensive loss, revenues for the six months ended…

Continue Reading

ThursdaySep 30, 2021 10:23 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Group of Patients in Potentially Pivotal Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. According to the update, further patient enrollment, randomization and dosing is currently underway as well as a robust lineup of globally located clinical sites, which are advancing toward activation and enrollment. “As one of the most aggressive, deadly and treatment-resistant cancers that…

Continue Reading

ThursdaySep 30, 2021 9:49 am

NetworkNewsBreaks – Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Releases Pricing of Proposed Public Offering

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products by Bidi(R) Vapor LLC, has announced an underwritten public offering of 4,700,000 shares of its common stock and accompanying warrants. According to the announcement, the pricing of the public offering, which included each share of common stock being sold together with 0.75 warrants for a combined price of $1.70, is $8 million before deducting typical underwriting discounts and offering expenses. The company anticipates using net proceeds from the offering to fund working capital and general corporate purposes. KAVL anticipates granting the underwriters a 45-day option to purchase up to an…

Continue Reading